Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Executive Summary

• Rapid Dose Therapeutics Corp. will issue 362,708 common shares at a deemed price of $0.13 to satisfy $47,153.98 of accrued interest on its amended and restated secured convertible notes dated December 1 2025.
• The share issuance is expected no later than January 15 2026 and the shares will be subject to a hold period of four months and one day.
• This action follows an extension of maturity dates for $3,084,445 of promissory notes and related warrants to November 30 2026.

Key Details

• Notes Background: Amended and restated secured convertible notes issued on December 1 2025; interest rate 18% per annum, compounded monthly.
• Accrued Interest Paid in Shares: $47,153.98 of accrued interest will be satisfied by issuing 362,708 common shares at a deemed issue price of $0.13 per share (CSE closing price on December 31 2025).
• Issuance Timeline: Shares to be issued no later than January 15 2026.
• Hold Period: Issued shares subject to a lock‑up expiring four months and one day after issuance.
• Financing History: Original private placement financing (2023) closed all four tranches, raising $3,134,445 principal amount of notes and 15,672,225 warrants at $1.00 per unit.
• Extension Agreement: Noteholders with $3,084,445 of promissory notes agreed to extend maturity to November 30 2026; accompanying 15,422,225 warrants extended to the same date.
• Prepayment Rights: Company may prepay the notes with ten days’ notice without additional bonus.

Notable Quotes

(No direct quotes were provided in the release.)